



CORPORATE PROFILE


Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care.

4 Science Park
New Haven, CT 06511
Phone: 1.203.787.7888
Fax: 1.203.901.128
<http://www.precipiodx.com/index.html>
info@precipiodx.com

CORE IR
Scott Gordon
President
377 Oak Street
Garden City, NY 11530
516.222.2560
www.coreir.com
scottg@coreir.com

STOCK PERFORMANCE

Symbol	prpo
Exchange	NSC
Market Cap.	32.11m
52 Week Range	4.00 - 47.70
Close	4.7375
Volume	3
Shares Outstanding	6,607,966
As of Aug 7, 2017 3:55 pm	



MANAGEMENT TEAM

Ilan Danieli - Founder & CEO

Carl Iberger - CFO

Stephen Miller - Chief Commercial Officer

Zaki Sabet - Chief Operating Officer

Ayman Mohamed - VP R&D

BOARD OF DIRECTORS

Mark Rimer - Director

Robert M. Patzig - Chairman of the Board of Directors

Ilan Danieli - CEO & Director

Michael A. Luther, Ph.D. - Director

Sam Riccitelli - Director

RECENT HEADLINES

[Aug 1, 2017 - Precipio Announces Proposed Public Offering](#)

[Jul 24, 2017 - Precipio Announces Commencement of a Multi-Party Study to Demonstrate the Impact of Academic Pathology Expertise on Diagnostic Accuracy](#)

[Jul 12, 2017 - Precipio Announces Agreement with Clearbridge Health for Liquid Biopsy and Diagnostic Services in Asia](#)

[Jul 12, 2017 - Precipio to Ring the Nasdaq Stock Market Opening Bell on July 12, 2017](#)

[Jul 11, 2017 - Precipio, Inc. \(Nasdaq: PRPO\) to Ring The Nasdaq Stock Market Opening Bell](#)